gland pharma glp-1 manufacturing capacity India's pharmaceutical industry is witnessing another massive strategic move 💊📈 Anupam Rasayan plans to acquire up to 43% stake in Bliss GVS in a ₹1,369 crore deal, signaling stronger expansion, integrated 🚨 FDA Moves to Permanently

#CardiovascularDrugs #Cardiology #HeartHealth #PharmaceuticalIndustry #CardiovascularDisease #PharmaInnovation To view or add a comment, sign in : : The biosimilars market is expected to reach USD 72.29 billion by 2035 from USD 35.04 billion in 2025, at a CAGR of 7.5% during the forecast period

Bian J, Liebert A, Bicknell B, Chen X-M, Huang C, Pollock CA (2022) Faecal microbiota transplantation and chronic kidney disease

Con: No GLP-1 friendly standard When it comes to label claims, the lack of standardization of GLP-1 friendly is the ultimate con for brands looking to enter this space

At 2mg daily, that's about 60mg

The True Meaning of Patient Autonomy Patient autonomy is the right to make informed decisions about your health

More serious side effects can occur, although they are less common